Company ProfilePremium

Balaxi Pharmaceuticals Limited

Company Profile Analysis

Ticker: BALAXI.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Balaxi Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

1942

62 Employees

Balaxi Pharmaceuticals Limited logo

Balaxi Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Balaxi Pharmaceuticals Limited Overview

Balaxi Pharmaceuticals is a Hyderabad-headquartered, promoter-controlled, branded-generics distributor-turned-manufacturer that sells essential medicines into frontier and semi-regulated markets — principally Angola in Africa and five Central American and Caribbean markets (Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua). Its moat, as management frames it, is the combination of country-level product registrations (964 at FY26; 980 by Q1 FY27), local warehousing (38 warehouses) and on-ground expatriate-led commercial teams, now complemented by its first captive oral-solid-dosage plant at Jadcherla, Telangana, which received its manufacturing licence in May 2026 and WHO-GMP certification in August 2026. The company is small (FY26 revenue INR 270.17 crore) and currently in a profitability trough: EBITDA margin compressed from roughly 18–20% in FY22–FY24 to 4.2% in FY26, driven by a working-capital-heavy push into Angola's institutional channel, plant readiness costs and new-market spending, culminating in a CRISIL downgrade and a share-price decline of roughly 89% from its peak.


Company's own description (AR FY26)

Balaxi describes itself as a branded, IPR-driven pharmaceutical company serving frontier and semi-regulated markets across Africa and Latin America. Its operating model, in the company's words, is built around identifying product gaps, securing local registrations, maintaining availability through warehousing and distribution, and building brands where access to affordable medicines is structurally important. The FY26 annual report is themed "Affordable Access – Integrated Scale" and articulates four operating pillars: access-led market presence, a registration-led moat, manufacturing-led control (the Jadcherla plant), and distribution-led reach (warehouses, local teams and fleet). The company labels its model "produce, stock and sell" and describes a deliberate evolution from "asset light" to "asset right."

The company's articulated value chain is: market research and therapeutic-gap identification → product selection (essential, OTC, generic and branded-generic) → dossier preparation and in-country registration → manufacturing (Jadcherla) or sourcing from approved third-party manufacturers → stocking in local warehouses → sale through wholesalers, pharmacies, healthcare professionals, institutions and hospitals → brand and channel development with pharmacists and physicians.

Independent characterisation

In substance, Balaxi has historically been an importer-distributor with owned brands and owned registrations rather than a pharmaceutical manufacturer. "IPR" in Balaxi's usage refers chiefly to ownership of marketing authorisations (product registrations) and trademarks in its destination markets, not patents or proprietary molecules. Products were sourced from WHO-GMP certified contract manufacturers in India and China (and, per the AR FY26 risk table, Portugal), shipped to local subsidiaries, warehoused, and sold under the Balaxi brand umbrella. The economic value lies in (i) the time and cost of building registration portfolios in markets where registration takes 12–24 months (AR FY26), (ii) the logistics and credit capability to keep stock available in markets with fragmented distribution, and (iii) the gross-margin spread between Indian ex-factory generic costs and destination-market prices — evidenced by consolidated gross margins of 43–47% in FY24–FY26.

The FY26 transition introduces a captive manufacturing leg (Jadcherla OSD plant) intended to internalise part of the contract-manufacturing margin and improve supply control. The plant is small relative to group needs (two 37-station compression machines, three packing lines) and will be commercialised product-by-product.

A second, less-advertised feature of the model is balance-sheet intensity: inventory of around 120 days and receivables of 138 days at FY25 (CRISIL), with institutional-channel collection cycles of 180–240 days. Balaxi effectively extends trade credit and carries stock in hard-currency-scarce markets, which exposes it to currency devaluation (Angola, 2023) and counterparty payment risk.

Revenue model and mix

DimensionDisclosureSource
Revenue modelProduct sales (100% product revenue; no service, subscription or licensing revenue disclosed)AR FY26
Business linesPharmaceuticals (core); ancillary building hardware/construction materials (discontinuation initiated FY26); branded consumer products historically (e.g., "YAP" biscuits launched Feb 2019)AR FY26; CRISIL; IIFL summary
Branded vs generic (portfolio)Branded generics ~40%, generics ~60% (FY26 portfolio)AR FY26
Branded vs generic (Q1 FY27 sales)54% branded, 46% genericsQ1 FY27 investor presentation (Quartr summary)
Geography (FY26)LATAM INR 111.29 crore (41% of revenue on a rupee basis); Angola and other INR 158.88 crore (derived). AR FY26 elsewhere states "Angola 52% / LATAM 48%" — internally inconsistentAR FY26
ChannelsWholesalers, pharmacies, healthcare professionals, institutional/hospital buyers (growing in Angola)AR FY26; CRISIL Apr 2026
Customer typesPrivate pharmacy and wholesaler trade; government and private hospitals/institutions (Angola); retail end-consumers paying out-of-pocketAR FY26
End-marketsPrimary care, anti-infectives, analgesics, anti-malarials, vitamins, chronic-care genericsAR FY26

Value-chain position

Balaxi sits in the middle and downstream of the generic pharmaceutical value chain: it does not develop APIs or new formulations, but controls registration, import, warehousing, distribution and brand-building in destination markets. With Jadcherla, it adds finished-dosage manufacturing for selected OSD products. It competes against both large Indian exporters (which sell through local distributors or own subsidiaries) and local importers/distributors.

Strategy

Stated strategy themes (AR FY26 and investor presentations, paraphrased)

The FY26 annual report's strategy is organised around three reinforcing pillars — registration-led market access, distribution infrastructure and captive manufacturing — and the "asset light to asset right" transition. Management states it targets top-two positions in each geography, uses an Indian-expatriate leadership model combined with local hiring, and prioritises depth before scale in market entry. Earlier presentations (2020–2022) set a vision of expanding into 20 frontier markets within five years; that target has not been met (six operating markets at FY26) and is no longer emphasised.

Strategic initiatives — last 24 months

InitiativeDescriptionStatus (Oct 2026)Timeline (AR FY26)
Jadcherla commercialisationPhased, product-by-product commercial production of OSD products for Angola and LATAMCommercial production started for initially approved products (Aug 2026)H1 FY27
WHO-GMP certificationCertification to strengthen institutional and tender credentialsReceived Aug 2026, valid to Aug 2029FY27 (achieved)
Angola institutional channel normalisationTighter customer selection, receivable ageing and exposure limitsIn progressH1–H2 FY27
LATAM expansion — Ecuador and ChileEntry into larger, higher-spend LATAM marketsSubsidiary formed (Ecuador); expansion initiatedFY27–FY28
Building-hardware discontinuationExit ancillary business to focus capital on pharmaInitiated FY26FY27
Branded-share increaseRaise branded generics share (40% portfolio) for pricing and loyaltyOngoingOngoing
Registration deepening49 new in FY26; 16 in Q1 FY27; 200+ pipelineOngoingOngoing
Digital infrastructureSAP ERP, digitised regulatory workflows, CRM, dashboards; being "AI enabled"OngoingOngoing
New-market entry planningSelective replication in new frontier markets; AR SWOT mentions South-East Asia and CISPlanningFY27–FY28
Dubai hub capitalisationUSD 5 million (Aug 2024) and up to USD 4 million (Nov 2025) equity into Dubai WOSApproved—

ESG and cost programmes

No quantified cost-reduction programme or ESG target is disclosed. CSR focuses on school construction in Hyderabad.

Medium-term targets and guidance

Balaxi provides no quantitative revenue, margin or earnings guidance. AR FY26 states management expects better operating leverage as Jadcherla scales, Angola working capital improves and LATAM grows; the Q1 FY27 presentation repeats the expectation of improvement as operating leverage strengthens. CRISIL (Apr 2026) expected FY26 revenue of ~INR 280 crore (actual 270.17) and operating margin ~5% (actual 4.2%), with debt-protection metrics recovering in FY27; its upgrade trigger is net cash accruals above INR 25 crore, and its downgrade trigger is operating margin below 5% in the coming fiscal.

Products & Services

Portfolio scale

MetricValueDateSource
Registered products (country-registrations)548Oct 2020NSE investor presentation
Registered products556May 2021NSE investor presentation
Registered products564Nov 2021NSE investor presentation
Registered products964 (49 added in year; 200+ filed/pipeline)FY26AR FY26
Registered products980 (16 added in Q1)Q1 FY27Q1 FY27 presentation (Quartr)
Distinct products in catalogue~289 (sum of category counts in AR FY26 "Our Offerings")FY26AR FY26 (analyst sum)

"Registrations" count each product-country approval; a single molecule-strength registered in five countries counts five times. The distinct catalogue is therefore roughly 289 SKUs/products, consistent with third-party descriptions of "300+ products."

Catalogue by therapeutic category (AR FY26 "Our Offerings")

Therapeutic categoryNumber of productsTypical customerNotes
Antibiotics75Pharmacies, hospitals, institutionsLargest category; antibiotics ~41% of therapeutic mix
Analgesics57Pharmacies, OTC~14% of therapeutic mix
Medical devices32Pharmacies, hospitalsProduct types not specified
Vitamins26Pharmacies, OTC—
Anti-malaria16Pharmacies, institutions (Angola)~8% of therapeutic mix
Erectile dysfunction8Pharmacies—
Hypertension7PharmaciesChronic care
Anti-asthma6Pharmacies—
Steroids6Pharmacies, hospitals—
Anti-helminthic5Pharmacies—
Anti-ulcer5Pharmacies—
Hygiene5Retail—
Anticholinergic4Pharmacies—
Dietary supplements4Retail—
Diuretics4Pharmacies—
Hormones4Pharmacies—
Other4——
Anti-emetic3Pharmacies, hospitals—
Bronchodilator3Pharmacies—
Local anaesthetic3Hospitals—
Anaemia2Pharmacies—
Anti-diarrhoea2Pharmacies—
Antihistamine2Pharmacies—
Hypotension2Pharmacies—
Antacid1OTC—
Anti-tuberculosis1Institutions—
Insect repellent1Retail—
Laxative1OTC—

Balaxi does not publicly disclose individual brand names, specifications, launch years or pricing for its products in the sources reviewed; all products are marketed under the Balaxi corporate brand. The catalogue is therefore presented at category level, which is the most granular level publicly disclosed.

Portfolio mix

Mix dimensionFY26 (AR, portfolio basis)Q1 FY27 (presentation, sales basis)
Branded generics40%54%
Generics60%46%
Tablets41%60% (tablets)
Capsules16%—
Liquids15%40% (injectables/liquids combined)
Injectables12%—
Others16%—
Antibiotics (therapeutic)41%—
Analgesics14%—
Anti-malarials8%—
Others (therapeutic)37%—

The two bases are not like-for-like; the higher branded share in Q1 FY27 sales may reflect mix effects or a different definition and should not be read as a step-change without confirmation.

Manufacturing "product" — Jadcherla OSD facility

ParameterDetail (AR FY26)
LocationPlots S-10, S-11, S-12, Pharma SEZ, Jadcherla, Mahabubnagar, Telangana
Land / built-up area13,855 sq m / 3,373 sq m
Dosage formsOral solid dosage — tablets and capsules
Design standardsWHO-GMP, CDSCO, PIC/S
Granulation10 kg and 150 kg lines (wet and dry)
CompressionTwo double-rotary 37-station machines
PackingTwo blister lines (PVC/Alu and Alu/Alu), one strip line
QCTwo HPLC units, FTIR, UV spectrophotometry, dissolution, microbiology, stability chambers
UtilitiesHVAC, purified water, compressed air, two 200 kW DG sets
StatusLicence received May 2026; WHO-GMP certification August 2026 (valid to Aug 2029); commercial production commenced for initially approved products

Non-pharma lines

Building hardware / construction materials (Angola) — being discontinued; product detail not disclosed. Branded consumer products ("YAP" biscuits, launched Feb 2019) — current status not disclosed.

Financial Narrative

All figures are consolidated, INR crore, from AR FY26 five-year snapshot and Board's Reports FY25/FY26 unless noted. Blank cells = not publicly disclosed in sources reviewed.

Income statement (chartable)

Notes: Finance costs FY22–FY24 and PBT/tax FY22–FY24 from StockAnalysis (consistent with AR where overlapping). AR FY26 reports FY22 and FY23 EPS on pre-split INR 10 face value (47.66 and 45.81); split-adjusted figures from TipRanks align with dividing by five. FY22 dividend of INR 0.50 on INR 10 face value = INR 0.10 split-adjusted; it was paid in July 2022 (FY23 cash flow) as a final dividend for FY22. FY25 revenue appears as INR 292.56 crore (AR) and INR 294.92 crore (CRISIL "operating income"); total income was INR 288.84 crore after negative other income of INR 3.72 crore (FX loss).

Margins and growth (chartable)

Revenue CAGR: FY22–FY26 (4 years) = −0.8%; FY21–FY26 (5 years, FY21 base ~INR 231 crore per Screener) = +3.2%. Screener's machine-generated five-year sales growth figure (~6%) uses a different window.

Balance sheet (chartable)

Notes: Total assets FY22–FY25 from TipRanks (labelled by calendar year on that site; mapped to fiscal years by matching equity). Cash and equivalents, short-/long-term debt split, net debt, goodwill and intangibles are not publicly disclosed in the sources reviewed. CRISIL's adjusted net worth for FY25 (INR 204.9 crore) differs from the AR figure (INR 231.74 crore), likely due to analytical adjustments. FY26 equity rose by INR 17.3 crore despite PAT of only INR 1.42 crore, implying a material positive other-comprehensive-income item (most plausibly foreign-currency translation); the composition is not disclosed in sources reviewed. Book value per share = equity / 5.52 crore shares (FY22–FY23 approximate, as share count was lower before warrant conversions).

Cash flow (chartable)

Notes: Cash-flow statement line items are not publicly disclosed in the sources reviewed. Dividend paid FY23 is an analyst estimate (INR 0.50 × ~1.0 crore pre-split shares). Preferential-issue receipts by year are analyst allocations of the INR 47.57 crore total: INR 1.10 crore equity plus 25% warrant upfront (INR 12.06 crore) in Oct 2022; INR 6.96 crore of conversions to Sep 2023 per the SoDV filing (assigned FY24, although part may fall in FY23); remaining conversions largely Jan–Apr 2024 (split between FY24 and FY25 — the allocation shown is indicative only). The company confirms proceeds were fully utilised by Q4 FY26. A 2021 Quartr summary noted that working-capital growth constrained FY21 operating cash flow — a pattern consistent with the subsequent receivable build-up.

Ratios (chartable; analyst calculations from figures above)

Notes: ROIC for FY22–FY24 uses StockAnalysis operating income (49.72, 54.81, 44.64) as EBIT proxy; FY25–FY26 use AR EBITDA less D&A. Invested capital = equity + debt. Net debt/EBITDA cannot be computed (cash not disclosed). CRISIL's figures differ: interest coverage 16.35x (FY24) and 8.64x (FY25); adjusted gearing 0.10x (FY24) and 0.25x (FY25); current ratio 4.52x (FY25). Cash conversion cycle: CRISIL reports inventory of ~120 days and receivables of 138 days at FY25 (gross current assets 295 days); payable days are not disclosed, so a full CCC cannot be computed. The AR FY26 MD&A ratio table (current ratio 1.27, ROE 47%, inventory turnover 124,455x, net profit ratio 6.37%) appears to relate to the standalone entity and contains internal inconsistencies (e.g., ROE 47% alongside return on net worth 3.95%); it is not relied upon.

Quarterly trajectory (chartable)

Notes: Q1 FY26 and Q1 FY27 as reported (NSE outcome 5 Aug 2026; an alternate Q1 FY26 figure of INR 70.74 crore appears in one secondary source). Q2–Q4 FY26 derived from cumulative H1 (INR 126.92 crore, IIFL), 9M (INR 199.45 crore, CRISIL) and full-year (AR) disclosures. Q1 FY27 gross margin 46.5% (+241 bps YoY); employee costs INR 11.36 crore vs INR 8.41 crore (+35%); PBT INR 2.09 crore; effective tax 37.8%; basic EPS INR 0.24. Standalone Q1 FY27: revenue INR 15.58 crore, net loss INR 1.25 crore, attributed to Jadcherla depreciation and staffing.

Commentary on trends, inflections and drivers

Revenue. The five-year revenue line is essentially flat with two large swings. FY23's peak (INR 336 crore) included favourable Angolan exchange effects; management noted in the Q1 FY23 call that extra exchange-rate profit from Angola would not recur. FY24's 28% contraction followed the kwanza devaluation, which shrank rupee-translated Angolan sales and forced pricing resets. FY25's 21% rebound came from Angolan demand recovery and new institutional business (CRISIL). FY26's 7.7% decline reflects a deliberate slowdown of the Angolan institutional channel as receivables ballooned, plus the hardware wind-down. Q1 FY27's 14% YoY growth is the first sign of reacceleration but off a weak base.

Gross margin vs EBITDA margin divergence. The single most important analytical observation is that gross margin has been stable to improving (44.2% in FY26, 46.5% in Q1 FY27) while EBITDA margin collapsed from 18.3% (FY24) to 4.2% (FY26). The compression is therefore entirely below gross profit: selling, general and administrative costs rose from INR 65.7 crore (FY24) to INR 89.4 crore (FY25) to INR 110.8 crore (FY26) per StockAnalysis — a 69% increase in two years against flat revenue. CRISIL attributes this to promotional and marketing spend to penetrate institutional sales; AR FY26 adds Jadcherla readiness costs, regulatory/quality-system investment and new-market build-out. This is an operating-leverage problem, not a pricing problem, which is the basis of the bull case.

Earnings quality. PAT has been volatile and FX-sensitive: other income swung from +INR 2.82 crore (FY26) to −INR 3.72 crore (FY25, FX loss of ~INR 6.1 crore per StockAnalysis). The FY26 effective tax rate of 73% indicates taxable profits in some jurisdictions offset by losses elsewhere. FY22–FY23 earnings had low effective tax rates (13–19%), consistent with profits booked in the UAE hub.

Balance sheet. Net working capital has grown from INR 78 crore (FY22) to INR 189 crore (FY26) — 70% of revenue — absorbing almost all equity raised and retained. Debt has risen 16-fold since FY22 (INR 3.6 crore to INR 57.7 crore), though leverage remains modest at 0.23x equity. The financial risk is less about solvency and more about the collectability of Angolan institutional receivables and the cash generation of the business: CRISIL expected net cash accruals of only ~INR 4 crore in FY26.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRelationshipFunctionSource

Balaxi Pharmaceuticals Limited

India

Parent (listed)

Holding, sourcing, export, Jadcherla manufacturing

AR FY26

Balaxi Global FZCO (formerly Balaxi Global DMCC; renamed 2 May 2025)

Dubai, UAE

Wholly-owned subsidiary

International distribution hub; holding company for operating subsidiaries

AR FY26

Balaxi Healthcare Ecuador S.A.S.

Ecuador

Wholly-owned subsidiary (direct)

Expansion vehicle (nascent)

AR FY26

Balaxi Healthcare Guatemala, S.A.

Guatemala

Step-down WOS

Local distribution; central/WHO-GMP certified warehouse

AR FY26

Balaxi Healthcare Dominicana, S.R.L.

Dominican Republic

Step-down WOS

Local distribution

AR FY26

Balaxi Healthcare Honduras, S. de R.L. de C.V.

Honduras

Step-down WOS

Local distribution

AR FY26

Balaxi Healthcare El Salvador S.A. de C.V.

El Salvador

Step-down WOS

Local distribution

AR FY26

Balaxi Healthcare Angola

Angola

Step-down WOS

Largest market; retail and institutional distribution

AR FY26

Balaxi Healthcare Nicaragua

Nicaragua

Step-down WOS (from 1 Apr 2025)

Nascent market

AR FY26

Balaxi Healthcare Centrafrique SARL

Central African Republic

Struck off 10 Apr 2025

Ceased

AR FY26

Balaxi Healthcare Chile

Chile

Listed in CRISIL consolidation (Nov 2024 onward) but not in AR FY26 subsidiary list — discrepancy

Targeted expansion

CRISIL; AR FY26

Business Lines

Business line (historical definition)ContentsStatusSource

Pharmaceuticals

Branded generics, generics, OTC, medical devices across ~28 therapeutic categories

Core

AR FY26; NSE presentation Q2 FY22

Ancillary — building hardware / construction materials

Branded construction-related materials sold in Angola

Discontinuation initiated FY26

AR FY26; CRISIL

Branded consumer products

FMCG (e.g., "YAP" biscuits from 2019)

Not separately referenced in AR FY26; status not disclosed

IIFL summary

Revenue by Segment and Revenue by Segment (%)

Segment / RegionFY24FY25FY26

Consolidated revenue (INR Cr)

241.29292.56270.17

LATAM revenue (INR Cr)

—100.26111.29

Angola and other revenue (INR Cr)

—192.30158.88

LATAM share of revenue (%)

—34.341.2

Angola and other share of revenue (%)

—65.758.8

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

279.39336.43241.29292.56270.17

Revenue growth YoY (%)

20.920.4-28.321.2-7.7

Gross profit (INR Cr)

83.79134.01112.61126.86119.30

EBITDA (INR Cr)

55.1859.1744.0833.5011.35

Depreciation and amortisation (INR Cr)

———1.892.15

EBIT (INR Cr)

———31.619.20

Finance costs (INR Cr)

0.140.501.682.933.90

Exceptional items (INR Cr)

00-38.2900

Profit before tax (INR Cr)

54.5256.922.0228.675.29

Tax expense (INR Cr)

6.8710.964.403.603.88

Net income / PAT (INR Cr)

47.6645.96-2.3925.071.42

Basic EPS, split-adjusted (INR)

9.539.16-0.464.540.26

Diluted EPS, split-adjusted (INR)

9.539.08-0.464.540.26

Dividend per share, split-adjusted (INR)

0.100000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

30.039.846.743.444.2

EBITDA margin (%)

19.717.618.311.54.2

EBIT margin (%)

———10.83.4

PBT margin (%)

19.516.90.89.82.0

Net margin (%)

17.113.7-1.08.60.5

Effective tax rate (%)

12.619.3217.812.673.3

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

176.0240.0258.0310.0—

Current assets (INR Cr)

141.00193.51210.17242.77251.43

Current liabilities (INR Cr)

63.2753.1354.2054.5362.16

Net working capital (INR Cr)

77.74140.38155.97188.23189.27

Total debt incl. leases (INR Cr)

3.6413.3119.4053.4357.65

Total equity / net worth (INR Cr)

113.16182.88201.27231.74249.08

Book value per share, split-adjusted (INR)

22.633.136.542.045.1

Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividends paid (INR Cr)

00.5000

Buybacks (INR Cr)

00000

Equity raised via preferential issue (INR Cr)

013.176.9527.450

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

52.931.1-1.211.60.6

ROA on closing assets (%)

27.119.2-0.98.1—

ROIC, notional 25% tax (%)

31.921.015.28.32.2

Current ratio (x)

2.233.643.884.454.04

Debt to equity (x)

0.030.070.100.230.23

Gross debt to EBITDA (x)

0.070.220.441.595.08

Interest coverage, EBITDA/finance cost (x)

388.6118.326.211.42.9

Asset turnover (x)

1.591.400.940.94—

Income Statement

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

70.7156.2172.5370.7280.68

PAT (INR Cr)

0.290.210.300.621.30

Revenue by Region and Region Margins & Growth (%)

RegionFY2025FY2026

LATAM revenue (INR Cr)

100.26111.29

Angola and other revenue (INR Cr)

192.30158.88

LATAM growth YoY (%)

—11.0

Angola and other growth YoY (%)

—-17.4

Valuation Snapshot

MetricValueAs ofSource

Latest verified price (INR)

23.39

14 Sep 2026

Anand Rathi

52-week high / low (INR)

47.71 / 15.20

Sep 2026

Anand Rathi

1-year return (%)

-48.4

14 Sep 2026

Anand Rathi

3-year return (%)

-74.6

14 Sep 2026

Anand Rathi

5-year high, split-adjusted (INR)

216.04

as of Mar 2025 data

Equentis

Drawdown from 5-year high to latest (%)

-89

Analyst calc

—

Preferential issue price, split-adjusted (INR)

90.20 (INR 451 / 5)

2022–2024

NSE filings

Valuation Multiples

MultipleBalaxiBasis

P/E (TTM)

~53x

TTM PAT INR 2.43 crore (FY26 1.42 + Q1 FY27 1.30 − Q1 FY26 0.29)

P/E (FY26)

~91x

FY26 PAT INR 1.42 crore

P/B

~0.52x

FY26 equity INR 249.08 crore

EV/Sales (TTM)

≤0.67x

EV ≈ INR 186.7 crore (market cap + gross debt; cash not netted as not disclosed); TTM revenue INR 280.1 crore

EV/EBITDA (FY26)

≤16.4x

FY26 EBITDA INR 11.35 crore

Caplin Point P/E (reference)

~31x

INR 2,623 (27 Jul 2026) / FY26 EPS INR 84.36

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share, split-adjusted (INR)

0.100000

Shares outstanding, split-adjusted (crore)

5.005.125.455.525.52

Analyst Ratings & Targets

DateAgencyRating / outlookFacilityKey reasoning

7 Sep 2022

CRISIL

BBB+ / Stable (assigned)

INR 50 crore fund-based

Established Angola/LATAM position

14 Aug 2023

CRISIL

BBB+ / Negative

INR 50 crore

Kwanza devaluation loss

5 Nov 2024

CRISIL

BBB+ / Stable

—

FY24 recovery

13 Nov 2025

CRISIL

BBB+ / Negative

INR 35 crore

Profitability pressure

1 Apr 2026

CRISIL

BBB / Stable (downgrade)

INR 35 crore working capital (Yes Bank)

Marketing spend for institutional channel; ~5% margin; stretched working capital

Analyst Conclusions

Management guidance

No numerical guidance. Management's stated FY27 priorities: Jadcherla commercial production (H1 FY27), Angola institutional channel normalisation (H1–H2 FY27), hardware discontinuation (FY27), WHO-GMP certification (achieved Aug 2026), Ecuador/Chile expansion and new-market planning (FY27–FY28), and continued branded-share growth. CRISIL expects debt-protection metrics to recover in FY27.

Consensus growth expectations

None available (no coverage).

Bull case (grounded in data)

  1. Operating leverage on an intact gross margin. Gross margin is 44–47% and improving; the margin collapse is in opex, which rose ~INR 45 crore in two years. If revenue grows to the FY23 level (~INR 336 crore) with opex held near FY26 levels, EBITDA could exceed INR 35 crore, and at FY24-like cost intensity, approach INR 50–60 crore — against a market capitalisation of ~INR 129 crore.

  2. Assets below book with a now-operational plant. At ~0.5x book, investors are paying roughly half of reported equity for a business with 980 registrations, 38 warehouses and a licensed WHO-GMP plant — the most capital-intensive phase is complete and the preferential proceeds are fully deployed.

  3. Early recovery signals. Q1 FY27 revenue grew 14% YoY to INR 80.68 crore, the highest quarterly revenue in at least five quarters; PAT more than quadrupled; gross margin expanded 241 bps; WHO-GMP certification followed within weeks.

Bear case (grounded in data)

  1. Receivables risk is the real issue. Net working capital of INR 189 crore is ~76% of equity; Angolan institutional collections run 180–240 days. Any impairment would erode book value — which explains the sub-book valuation — and CRISIL's downgrade trigger (operating margin <5%) was breached in FY26.

  2. Structural cost base and weak returns. ROE has averaged roughly 4% over FY24–FY26; Q1 FY27 annualised ROE is ~2%. Employee costs grew 35% YoY in Q1 FY27 — faster than revenue — as Jadcherla adds fixed costs before volumes arrive.

  3. Governance and disclosure discount. Combined promoter Chair/MD, material related-party transactions, history of acquiring promoter-group entities, CS turnover, an NSE fine and an NSE results query, and internally inconsistent geographic data — alongside the complete exit of foreign institutions — argue the discount may persist regardless of operating improvement.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it mattersTiming
Q2 FY27 resultsConfirms or refutes Q1 recovery; watch EBITDA margin vs 5% CRISIL thresholdLate Oct / Nov 2026
Receivable days and any provisioningCore balance-sheet riskEach half-year balance sheet (Sep 2026, Mar 2027)
Jadcherla utilisation and product approvalsMargin-accretion thesis; additional products pending approvalFY27
Angola FX and macroDevaluation risk; inflation trajectoryOngoing
LATAM growth rate and Ecuador/Chile first revenuesDiversification away from AngolaFY27–FY28
Hardware wind-down completionCleaner pharma-only P&LFY27
CRISIL annual reviewFurther downgrade vs stabilisation~Q4 FY27
Cash-flow disclosure (FY27 annual report)Operating cash conversionMid-2027
Shareholding changes (FII/DII re-entry, promoter buying)Sentiment signalQuarterly

Analyst verdict

Balaxi Pharmaceuticals is a small, promoter-controlled frontier-market pharma distributor at the most fragile point in its transition to an integrated manufacturer. The underlying franchise is real: nearly a thousand country registrations, a physical distribution network in markets few competitors serve directly, and gross margins in the mid-40s that have held up through currency shocks and channel turmoil. The capital project is done — the Jadcherla plant is licensed and WHO-GMP certified — and the market values the whole enterprise at roughly half its stated book equity.

However, the investment case rests almost entirely on the quality of that book equity, and the evidence there is uncomfortable. Working capital absorbs about 70% of revenue; the Angolan institutional channel that drove FY25's recovery has since become the primary drag, with 180–240-day collection cycles; and the company has not disclosed cash-flow details in the sources reviewed that would allow investors to judge cash conversion. Profitability has fallen from an EBITDA margin near 18% to just over 4% in two years, primarily on costs management chose to incur. CRISIL's downgrade, the exit of foreign institutions and reporting inconsistencies all point the same way.

The asymmetric outcome is clear in principle: if management can re-impose cost discipline, collect Angolan receivables without write-downs, and load the new plant, earnings could rebound several-fold off a tiny base, and a re-rating toward book value alone would roughly double the equity. The probability of that outcome, however, is not yet evidenced by more than one quarter of data. On balance, Balaxi is best characterised as a high-risk special situation, not an investable compounder: the stock is a call option on working-capital normalisation in Angola. The decisive monitorables are receivable days, provisioning and EBITDA margin in the next two reported half-years; until those turn convincingly, the governance and balance-sheet discount is justified.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryBackground (per AR FY26)Committee roles

Ashish Maheshwari (DIN 01575984)

Chairman and Managing Director

Executive, promoter

Founder; first-generation entrepreneur; Chartered Accountant; ~two decades in pharma (CRISIL); began supplying white-labelled formulations to importers

Member, Audit; Chair, Risk Management; Member, CSR

Minoshi Maheshwari (DIN 01575975)

Non-Executive Director

Non-executive, promoter

Co-founder; organisational and CSR leadership; reappointed by rotation at 82nd AGM (Aug 2025); retiring by rotation again at 83rd AGM

Member, NRC; Member, SRC; Chair, CSR

Kunal Mahendra Bhakta

Independent Director

Independent

Chartered Accountant; capital markets, fund management, investor relations, transactions

Chair, Audit; Chair, NRC; Chair, SRC

Gandhi Gamji

Independent Director

Independent

International trade across Africa and GCC; speciality chemicals

Member of Audit, NRC, SRC, Risk, CSR

Mangina Srinivas Rao

Independent Director

Independent

Strategy, project leadership, governance

Member, Audit

Akshita Ostwal (formerly Surana; DIN 10026552)

Independent Director

Independent

Practising company secretary, trademark agent, corporate law and IPR

—

Executive Leadership Team

NameTitleTenure / notesEducation / prior roles

Ashish Maheshwari

Managing Director

Since Balaxi takeover of listed entity (2017)

CA

Amol Mantri

Chief Financial Officer

With Balaxi Group since 2012

CA; US CPA

Pranav Maheshwari

Senior Vice President — Business Development (KMP)

Leads LATAM strategy; promoter family

BBA and Economics, Emory University

Paridhi Maheshwari

Head — Alternate Channels

Consumer-products portfolio; promoter family (relationship implied by surname; not confirmed)

MBA, London Business School

Aman Purohit

Company Secretary and Compliance Officer

Appointed 25 Mar 2026

—

Mohith Kumar Khandelwal

Former Company Secretary

Resigned 29 Jan 2026 (Nodal Officer from 6 Nov 2024)

—

Udayan Shukla

Former Company Secretary

Signed filings in 2022

FCS

Board & Management Changes

DateChangeContext

5 Sep 2024

Akshita Surana (now Ostwal) appointed Independent Director (postal ballot 6 Nov 2024)

Board refresh

29 Jan 2026

CS Mohith Kumar Khandelwal resigns

Second CS change in roughly four years

25 Mar 2026

Aman Purohit appointed CS

Two-month vacancy in compliance officer role during a downgrade period

Shareholding Trend

Holder categoryJun 2022Mar 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026

Promoter and group (%)

72.8666.8665.9965.9965.9965.9965.9965.99

Foreign institutions (%)

19.0017.2116.028.873.501.740.000.00

Domestic institutions (%)

0.030.020.020.020.020.022.562.56

Public / retail and others (%)

8.1115.9117.9625.1230.4932.2431.4531.45

Competitive Landscape

Key Competitors

CompetitorOverlap with BalaxiFY26 revenue (INR Cr)Positioning vs BalaxiSource

Caplin Point Laboratories

Central America and Caribbean branded generics; Francophone Africa; owned distribution

2,187.19

Closest model analogue; ~8x Balaxi's revenue; debt-free; vertically integrated with US-regulated sterile plants

Company results May 2026

Bliss GVS Pharma

Sub-Saharan Africa (anti-malarials, suppositories)

927.1 (operating revenue)

Africa-focused manufacturer-exporter; niche dosage-form leadership

StockAnalysis; IIFL

Lincoln Pharmaceuticals

Exports of anti-infectives and other formulations to Africa/LATAM

704.48 (total income)

Manufacturer-exporter with domestic business

DSIJ May 2026

Cipla

Africa (incl. Angola) branded generics and tenders

Not compiled

Scale player with institutional/tender strength

—

Sun Pharmaceutical Industries

LATAM and Africa emerging-markets generics

Not compiled

Global scale; different tier

—

Dr. Reddy's Laboratories

LATAM, Africa emerging markets

Not compiled

Global scale; different tier

—

Glenmark Pharmaceuticals

LATAM, Africa

Not compiled

Branded generics in emerging markets

—

Torrent Pharmaceuticals

Latin America (Brazil, Mexico)

Not compiled

Larger LATAM markets Balaxi does not serve

—

Ajanta Pharma

Africa branded generics

Not compiled

Strong Africa branded franchise

—

Local importers and distributors in Angola and Central America

Same channels

—

Price competitors; relationship-driven

—

Chinese generic exporters

Low-price generics in Africa

—

Price pressure in commodity generics

—

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricBalaxiCaplin PointBliss GVSLincoln Pharma

Revenue (INR Cr)

270.172,187.19927.1704.48

Revenue growth YoY (%)

-7.712.914.59.1

Gross margin (%)

44.260.451.7—

EBITDA / operating margin (%)

4.238.114.1—

Net margin (%)

0.529.7—12.5

R&D (% of revenue)

—4.6——

Company Snapshot

$31.2M

Revenue

62

Employees

1942

Founded

Hyderabad, India

Headquarters

SWOT Analysis

Strengths

  • Registration moat: 964 registrations at FY26 (49 added) rising to 980 by Q1 FY27, with 200+ in pipeline; registrations take 12–24 months each (AR FY26; Q1 FY27 presentation).
  • Resilient gross margin: 44.2% in FY26 and 46.5% in Q1 FY27, up from 30.0% in FY22, despite revenue decline (AR FY26).
  • Physical distribution: 38 warehouses, owned fleet, 500+ professionals including 80+ expatriates (AR FY26).
  • Licensed and WHO-GMP certified plant: Manufacturing licence May 2026; WHO-GMP certification August 2026 valid to 2029 (NSE; Tijori).
  • LATAM diversification gaining traction: LATAM revenue +11% to INR 111.29 crore in FY26 while group revenue fell 7.7% (AR FY26).
  • Modest leverage: Debt/equity 0.23x at FY26; current ratio ~4.0x (AR FY26 figures); no debt-funded capex pipeline (CRISIL Apr 2026).

Weaknesses

  • Profit collapse: EBITDA margin 4.2% in FY26 vs 18.3% in FY24; PAT INR 1.42 crore (AR FY26).
  • Working-capital intensity: Net working capital INR 189 crore = 70% of revenue; receivables 138 days and GCA 295 days at FY25 (AR FY26; CRISIL).
  • Angola concentration: More than 50% of revenue (CRISIL Apr 2026).
  • Cost creep: SG&A up from ~INR 66 crore (FY24) to ~INR 111 crore (FY26) on flat revenue (StockAnalysis).
  • Disclosure quality: NSE query on FY26 results discrepancy (Jun 2026); internally inconsistent geographic split and ratio tables in AR FY26.
  • Execution slippage on capex: Plant scope reduced from OSD + injectables (EU-GMP) to OSD only, ~18 months late versus 2022 schedule (Indian Pharma Post 2022; AR FY26).

Opportunities

  • Captive manufacturing margin capture: Replacing CMO supply for selected OSD products could lift gross-to-EBITDA conversion (AR FY26).
  • WHO-GMP-enabled tenders: Institutional and multilateral procurement eligibility (AR FY26 outlook).
  • Ecuador and Chile: Combined nominal GDP ~US$488 bn vs ~US$330 bn for Balaxi's five current LATAM markets (AR FY26 macro table).
  • Branded mix shift: 54% branded in Q1 FY27 sales vs 40% portfolio share (Quartr).
  • Operating leverage: At FY24 opex intensity, the existing ~44% gross margin would imply mid-to-high-teens EBITDA margins (analyst inference from AR five-year data).
  • Regulatory maturation: ARMED Level 3 target by 2027; Central American joint evaluation (AR FY26).

Threats

  • Kwanza devaluation recurrence: FY24 precedent of INR 38.29 crore exceptional loss (AR FY25).
  • Institutional receivable losses: Collection cycles of 180–240 days (CRISIL Apr 2026); any write-off would hit a thin equity cushion relative to receivables.
  • Further credit downgrade: CRISIL downward trigger is operating margin below 5% — FY26 was 4.2% (CRISIL Apr 2026).
  • Competitive pressure: Caplin Point, with ~8x the revenue and ~38% EBITDA margin, targets the same Central American markets and is expanding into Chile (135+ product licences there) (Caplin disclosures).
  • Macro fragility: Angola GDP ~2.1%, inflation 15.7% (Dec 2025) (AR FY26).
  • Investor disengagement: FII holdings fell from 16.02% to nil within 15 months; share price down ~89% from peak (Upstox; Equentis; Anand Rathi).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Balaxi Healthcare Nicaragua becomes WOS of Dubai hub AR FY26Formalises sixth LATAM/Africa operating entity
10 Apr 2025CAR subsidiary struck off AR FY26Exit from Central African Republic
2 May 2025Balaxi Global DMCC renamed Balaxi Global FZCO AR FY26Hub restructuring
30 May 2025FY25 results: revenue INR 292.56 crore, PAT INR 25.07 crore; BVR & Associates proposed as secretarial auditor NSE outcome; AR FY25Post-devaluation recovery year
30 May 2025Statement of deviation on preferential proceeds filed (no deviation) NSE filingCapital-use compliance
31 Jul 2025Notice of 82nd AGM and AR FY25 published NSE filing—
5–8 Aug 2025Q1 FY26 results (revenue INR 70.71 crore, PAT INR 0.29 crore); presentation states Jadcherla commissioning complete and qualification/validation done NSE presentation; QuartrMargin collapse becomes visible
25 Aug 202582nd AGM; NSE fine of INR 1,35,000 disclosed; 69.81% of votes polled Screener filings logCompliance lapse (nature not specified)
Sep 2025FII holding falls to 3.50% (from 16.02% in Mar 2025) UpstoxInstitutional exit
11 Nov 2025Q2 FY26 results (revenue down ~27% YoY); board approves up to USD 4 million equity into Dubai WOS; Jadcherla test licence obtained Screener; QuartrWeakest quarter; continued subsidiary funding
13 Nov 2025CRISIL revises outlook to Negative (BBB+ reaffirmed)Credit deterioration
14 Nov 2025Q2 investor presentation Screener—
Dec 2025FII holding 1.74% UpstoxContinued exit
28–29 Jan 2026Q3 FY26 results (9M revenue INR 199.45 crore, PAT INR 0.80 crore); plant described as inspection-ready CRISIL; NSE presentationProfitability near zero
29 Jan 2026Company Secretary resigns AR FY26Governance continuity risk
Late Mar – early Apr 2026Share price hits 52-week low of INR 15.20 Broker dataTrough valuation (~INR 84 crore market cap)
25 Mar 2026New Company Secretary (Aman Purohit) appointed; board meeting AR FY26Compliance role filled
30 Mar 2026Independent directors' separate meeting AR FY26Governance process
1–2 Apr 2026CRISIL downgrades to BBB/Stable; cites marketing spend for institutional penetration, 5% margin expectation, stretched working capital CRISIL; NSE intimationFirst downgrade since rating assigned
23 May 2026Manufacturing licence for Jadcherla received NSE outcome 28 May 2026Plant converts from project to operating asset
28 May 2026FY26 results: revenue INR 270.17 crore (−7.7%), EBITDA INR 11.35 crore (4.2%), PAT INR 1.42 crore; no dividend; ID reappointment recommended AR FY26Trough-year results
24–30 Jun 2026NSE queries discrepancy in FY26 results (employee benefit expense line shown incorrectly); company files clarification and revised outcome NSE clarification letterReporting-quality concern
31 Jul 2026AR FY26 and BRSR filed NSE filingDiscloses discontinuation of hardware, Ecuador/Chile plans
5 Aug 2026Q1 FY27 results: revenue INR 80.68 crore (+14% YoY), PAT INR 1.30 crore; WHO-GMP audit conducted, CAPA submitted NSE outcome; KalkineFirst YoY growth quarter in a year
6 Aug 2026Q1 FY27 presentation: 980 registrations (+16 in quarter), commercial production commenced at Hyderabad facility, 38 warehouses QuartrOperating milestones
24 Aug 202683rd AGM held via video conference NSE proceedingsRoutine; ID reappointment and director rotation on agenda
31 Aug 2026WHO-GMP certification for Jadcherla, valid through August 2029; manufacturing of initially approved products begins; further product approvals pending Tijori alertUnlocks institutional/tender credentials
14 Sep 2026Share price INR 23.39; ~48% down over one year, ~75% over three years Anand RathiValuation context
Oct 2026 (pending)Q2 FY27 results expected Univest previewKey test of recovery durability

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 2,793.9 Mn in FY2022 to INR 2,701.7 Mn in FY2026.
Balaxi Pharmaceuticals Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations2,793.93,364.32,412.92,925.62,701.7
Gross profit837.91,340.11,126.11,268.61,193

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Balaxi Pharmaceuticals Limited — Annual Report FY2025-26 (balaxipharma.in; filed with NSE 31 Jul 2026)
  2. Balaxi Pharmaceuticals — Board's Report FY2024-25 (via IIFL reproduction)
  3. NSE filings: investor presentations (12 Oct 2020; 26 May 2021; 2 Nov 2021; 24 Jun 2022; 5 Nov 2022; 1 Feb 2023; 5 Aug 2024; 13 Nov 2024; 13 Feb 2025; 8 Aug 2025; 29 Jan 2026); board outcomes (28 Feb 2024; 30 May 2025; 28 May 2026); warrant allotments (9 May 2023; 25 Jan, 23 Feb, 15 Mar, 3 Apr 2024); SoDV (2 Nov 2023; 30 May 2025); credit-rating intimations (15 Nov 2024; 2 Apr 2026); clarification letter (30 Jun 2026); AGM proceedings (24 Aug 2026); BRSR intimation (31 Jul 2026); NSE circular on name/symbol change (21 Sep 2017)
  4. CRISIL Ratings rationales: 7 Sep 2022; 14 Aug 2023; 5 Nov 2024; 13 Nov 2025; 1 Apr 2026
  5. Indian Pharma Post — preferential issue (Sep 2022); Jadcherla groundbreaking
  6. Quartr — Q1 FY27 earnings and investor presentation summaries (Aug 2026)
  7. Kalkine; MarketsMojo; Univest — Q1 FY27 coverage (Aug 2026)
  8. Tijori Alerts — WHO-GMP certification (31 Aug 2026)
  9. Screener.in; StockAnalysis; TipRanks; IIFL; Upstox; Emkay Global; Equitymaster; Anand Rathi; Groww; Sharpely; Research360; Equentis; ICICI Direct; AlphaStreet (Q1 FY23 call notes)
  10. Peer data: Caplin Point Laboratories FY26 results (Trendlyne, ScanX, FilingReader, StockAnalysis); Bliss GVS Pharma (StockAnalysis, IIFL); Lincoln Pharmaceuticals (DSIJ, May 2026)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.